

Indo American Hybrid Seeds India Private Limited

May 04, 2021

Rating

Facilities/Instruments	Amount (Rs. crore)	Ratings	Rating Action
Long Term Bank Facilities	40.00	CARE B+; Stable; ISSUER NOT COOPERATING* (Single B Plus; Outlook: Stable ISSUER NOT COOPERATING*)	Revised from CARE BB-; Stable (Double B Minus; Outlook: Stable) and moved to ISSUER NOT COOPERATING category
Total Bank Facilities	40.00 (Rs. Forty Crore Only)		

Details of instruments/facilities in Annexure

Detailed Rationale & Key Rating Drivers

CARE has been seeking No default statement from Indo American Hybrid Seeds India Private Limited to monitor the rating(s) vide e-mail communications March 31, 2021, April 01, 2021, April 06, 2021 and April 08, 2021 and April 16, 2021 and numerous phone calls. However, despite our repeated requests, the company has not provided the No default statement for monitoring the ratings. In line with the extant SEBI guidelines, CARE has reviewed the rating on the basis of best available information which however, in CARE's opinion is not sufficient to arrive at fair rating. The rating on Indo American Hybrid Seeds India Private Limited bank facilities will now be denoted as **CARE B+; Stable; ISSUER NOT COOPERATING***

Users of this rating (including investors, lenders and the public at large) are hence requested to exercise caution while using the above rating.

Detailed description of the key rating drivers

At the time of last rating on January 20, 2021 the following were the rating strengths and weaknesses

Key Rating Weaknesses

Modest scale of operations albeit to y-o-y growth

The scale of operations has grown at CAGR of 12.29% during FY18 to FY20 due to increasing orders from existing customers on back of favorable demand for hybrid seeds coupled with launch of 15 varieties new hybrid seeds during the period. The total operating income has grown from Rs. 77.05 crore in FY18 to Rs. 97.12 crore in FY20. Further, the company has registered the total operating income of Rs. 117.96 crore in 8MFY21 (provisional). The growth during 8MFY21 is attributed to launch of 15 seed varieties, kharif season and good monsoon prospects.

Financial risk profile marked by continues losses, leveraged capital and weak debt coverage indicators

The company reported operating loss of Rs.7.68 Crore in FY20 due to increase in cost of materials, employee expenditure, sales & promotion expenditure. IAHS has reported continues losses for the period FY18 to FY19 due to high R&D expenditure to develop hybrid seeds and high fixed costs which includes farm maintenance cost of around Rs.9-9.5 Cr per year irrespective of scale of operations. The capital structure is marked by high overall gearing ratio at 7.76x as on March 31, 2020 against 1.83x as on March 31, 2019 and 1.34x as on March 31, 2018 due to y-o-y increase in total debt levels to meet working capital requirements and erosion of net worth due to continuous loss.

Working capital intensive nature of operations

IAHS is engaged in manufacturing of agro seeds which is mainly dependent upon two major seasons Kharif (June to September) and Rabi (November to April), any climate imbalance would impact on operations of the company as it generates around 75% of its revenue during Kharif season. The company holds inventory required for one season to meet the orders. On account of which, the operating cycle of the company stood elongated at 165 days in FY20, though improved from 250 days in FY18 due to write off old and slow moving inventory. Further, the company receives credit period of 30 to 90 days from its suppliers and allows credit period up to 30 days to its customers. Working capital limits average utilization stood high ~85% for the last 12 months ending November 2020.

Exposure to agro climatic risk and intense competition from established players

The agriculture prospects in India is dependent on monsoon pattern. The country so far has witnessed favorable monsoon which bodes well for the agriculture season. In India, the hybrid seed market has considerable presence of MNC's players lead by Monsanto, DuPont, Syngenta, Nunhems India, etc, who have strong distribution network and huge financial muscle to carryout continuous R&D. Furthermore, the market is dominated by large domestic companies

(viz, Nuziveedu Seeds Private Limited, Rasi Seeds, Kaveri Seeds, etc) with large resources, strong distribution networks & R&D facilities.

Key Rating Strengths

Established track record and experienced management in Indian seed industry

IAHS is incorporated in 1965, by Late Dr. Manmohan Attavar a horticulturist, plant breeder and Padma Shri award winner in the year 1998 for his contribution in horticulture. He also has won many national and international awards in the field of horticulture. Since inception the company is engaged in extensive Research and Development, Bio-Technology, Production and marketing of hybrid seeds of vegetable crops, field crops, flower and ornamental plants. Post demise of Dr. Manohar Attavar, Mr. Arthur Santosh Attavar (son) is appointed as Chairman and Managing Director and Ms. Jane Ruhama Rashmi Attavar (daughter) as the Joint Managing Director for Floriculture division. Both the directors along with other directors has vast experience in the field of hybrid seeds for more than two decades held the company to gain more customer and suppliers. Further supported by the qualified management team who has relevant experience of more than two decades.

Established Research & Development division

IAHS is engaged in extensive Research and Development, Bio-Technology, Production and marketing of hybrid seeds of vegetable crops, field crops, flower and ornamental plants. The company has introduced tissue culture banana, vanilla and large cardamom commercially into the Indian market, and initiated restructuring of the Commercial Biotech operation and extension of the product line for the domestic Indian market. IAHS has won the national award in 1995 and 2000 for innovative research by the council of Scientific and Industrial Research (CSIR). Further, the company has Commercial Tissue Culture (TC), where IAHS produces disease free TC plants of select ornamental, fruit and planation crops. The seeds laboratory is an International Seed Testing Association (ISTA) accredited laboratory, where the seeds are labelled with red and green certificates for exports. IAHS has 10 laboratories engaged in research and development activities along with other allied services which management by team of 30 skilled professionals in agriculture comprising of 5 agro scientists and 10 Phd scholars.

Diversified geographical reach and product range

Due to long presence in the industry, the company has its presence across India with the distribution network of around 700 distributors and IAHS has various product under field crop division and vegetables crop division. The company has newly launched 15 varieties of seeds during last 3 years which propels the revenue growth in short to medium term.

Favorable prospects for hybrid seeds in India

Indian hybrid seed market expected to grow at CAGR of 11.00% for the period 2017-2030. The raising awareness among the farmers regarding the hybrid seeds and their substantial impact on per hectare production has led to growing sales of the hybrid seeds.

Analytical approach: Standalone

Applicable criteria:

[Criteria on assigning Outlook to Credit ratings](#)

[CARE's Policy on Default Recognition](#)

[Financial ratios – Non-Financial Sector](#)

[Liquidity Analysis of Non-Financial Sector Entities](#)

[Rating methodology – Manufacturing Companies](#)

About the Company

Bangalore based Indo American Hybrid Seeds India Private Limited (IAHS) was established as Proprietary concern by Late Dr. Manmohan Attavar in 1965. The firm reconstituted as a private limited company in 1997, and continued to engage in production of hybrid seeds of selective vegetables and field crops. The company has own farming land up to 400 acres and more than 5000 acres under contract farming for pollinating the seeds and the same will be tested in its laboratories for quality control.

Brief Financials (Rs crore)	FY19 (A)	FY20 (A)
Total operating income	91.66	97.20
PBILDT	0.63	-7.68
PAT	-6.08	-14.41
Overall gearing (times)	1.83	7.76
Interest coverage (times)	0.13	NM

A-Audited; NM: Not Meaningful

Status of non-cooperation with previous CRA: CRISIL has placed the ratings under Issuer Not Cooperating as per PR dated March 31, 2021.

Any other information: Not applicable

Rating History for last three years: Please refer Annexure-2

Annexure-1: Details of Instruments/Facilities

Name of the Instrument	Date of Issuance	Coupon Rate	Maturity Date	Size of the Issue (Rs. crore)	Rating assigned along with Rating Outlook
Fund-based - LT-Cash Credit	-	-	-	28.50	CARE B+; Stable; ISSUER NOT COOPERATING*
Fund-based - LT-Proposed fund based limits	-	-	-	3.65	CARE B+; Stable; ISSUER NOT COOPERATING*
Fund-based - LT-Working Capital Demand loan	-	-	September 2022	2.85	CARE B+; Stable; ISSUER NOT COOPERATING*
Fund-based - LT-Working capital Term Loan	-	-	September 2022	5.00	CARE B+; Stable; ISSUER NOT COOPERATING*

*Issuer did not cooperate; Based on best available information

Annexure-2: Rating History of last three years

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating history			
		Type	Amount Outstanding (Rs. crore)	Rating	Date(s) & Rating(s) assigned in 2021-2022	Date(s) & Rating(s) assigned in 2020-2021	Date(s) & Rating(s) assigned in 2019-2020	Date(s) & Rating(s) assigned in 2018-2019
1.	Fund-based - LT-Cash Credit	LT	28.50	CARE B+; Stable; ISSUER NOT COOPERATING*	-	1)CARE BB-; Stable (20-Jan-21)	-	-
2.	Fund-based - LT-Proposed fund based limits	LT	3.65	CARE B+; Stable; ISSUER NOT COOPERATING*	-	1)CARE BB-; Stable (20-Jan-21)	-	-
3.	Fund-based - LT-Working Capital Demand loan	LT	2.85	CARE B+; Stable; ISSUER NOT COOPERATING*	-	1)CARE BB-; Stable (20-Jan-21)	-	-
4.	Fund-based - LT-Working capital Term Loan	LT	5.00	CARE B+; Stable; ISSUER NOT COOPERATING*	-	1)CARE BB-; Stable (20-Jan-21)	-	-

*Issuer did not cooperate; Based on best available information

Annexure-3: Detailed explanation of covenants of the rated instrument / facilities: Not Applicable

Annexure 4: Complexity level of various instruments rated for this Firm

Sr. No.	Name of the Instrument	Complexity Level
1.	Fund-based - LT-Cash Credit	Simple
2.	Fund-based - LT-Proposed fund based limits	Simple
3.	Fund-based - LT-Working Capital Demand loan	Simple
4.	Fund-based - LT-Working capital Term Loan	Simple

Note on complexity levels of the rated instrument: CARE has classified instruments rated by it on the basis of complexity. This classification is available at www.careratings.com. Investors/market intermediaries/regulators or others are welcome to write to care@careratings.com for any clarification.

Contact us

Media Contact

Mradul Mishra

Contact no. – +91-22-6837 4424

Email ID – mradul.mishra@careratings.com

Analyst Contact

Name – Mr. Prajwal M R

Contact no.- 080-46625547

Email ID- prajwal.mr@careratings.com

Business Development Contact

Name: Nitin Dalmia

Contact no. : 080-46625526

Email ID: nitin.dalmia@careratings.com

About CARE Ratings:

CARE Ratings commenced operations in April 1993 and over two decades, it has established itself as one of the leading credit rating agencies in India. CARE is registered with the Securities and Exchange Board of India (SEBI) and also recognized as an External Credit Assessment Institution (ECAI) by the Reserve Bank of India (RBI). CARE Ratings is proud of its rightful place in the Indian capital market built around investor confidence. CARE Ratings provides the entire spectrum of credit rating that helps the corporates to raise capital for their various requirements and assists the investors to form an informed investment decision based on the credit risk and their own risk-return expectations. Our rating and grading service offerings leverage our domain and analytical expertise backed by the methodologies congruent with the international best practices.

Disclaimer

CARE's ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse or recall the concerned bank facilities or to buy, sell or hold any security. CARE's ratings do not convey suitability or price for the investor. CARE's ratings do not constitute an audit on the rated entity. CARE has based its ratings/outlooks on information obtained from sources believed by it to be accurate and reliable. CARE does not, however, guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE or its subsidiaries/associates may also have other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating /outlook assigned by CARE is, inter-alia, based on the capital deployed by the partners/proprietor and the financial strength of the firm at present. The rating/outlook may undergo change in case of withdrawal of capital or the unsecured loans brought in by the partners/proprietor in addition to the financial performance and other relevant factors. CARE is not responsible for any errors and states that it has no financial liability whatsoever to the users of CARE's rating. Our ratings do not factor in any rating related trigger clauses as per the terms of the facility/instrument, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and if triggered, the ratings may see volatility and sharp downgrades.

****For detailed Rationale Report and subscription information, please contact us at www.careratings.com**